What is the main difference between retatrutide and tirzepatide?

Tirzepatide is a dual agonist (GIP and GLP-1) and is FDA-approved as Mounjaro and Zepbound. Retatrutide is a triple agonist that adds glucagon-receptor activity and is investigational, not FDA-approved.

Is retatrutide better than tirzepatide for weight loss?

Phase 2 data for retatrutide showed dose-dependent weight loss among the largest reported for an incretin-based agent, but it is investigational and has not completed Phase 3, while tirzepatide has completed pivotal trials and is approved. Cross-trial comparisons are not the same as a head-to-head trial, and no approved comparison exists.

Are retatrutide and tirzepatide FDA-approved?

Tirzepatide is FDA-approved (Mounjaro for type 2 diabetes, Zepbound for weight management and obstructive sleep apnea). Retatrutide is not approved and remains in clinical trials.

Peptide Encyclopedia / Retatrutide vs Tirzepatide

Comparison

Retatrutide vs tirzepatide

Both are once-weekly injectable peptides in the incretin family, and both drive significant weight loss. The two biggest differences: how many receptors they hit, and whether they are actually approved. Here is the honest comparison.

Bottom line up front: tirzepatide is FDA-approved and has completed pivotal trials. Retatrutide is investigational and still in Phase 3. That approval gap matters more than any single weight-loss number.

	Retatrutide	Tirzepatide
Receptors	Triple: GIP + GLP-1 + glucagon	Dual: GIP + GLP-1
Brand names	None (LY3437943)	Mounjaro, Zepbound
Developer	Eli Lilly	Eli Lilly
FDA status	Investigational, Phase 3 (TRIUMPH)	Approved (diabetes, weight management, OSA)
Dosing	Once weekly SC, ~1–12 mg/wk in trials, titrated	Once weekly SC, approved titration schedule
Half-life	~6 days	~5 days
Reported weight loss	Phase 2: dose-dependent, among the largest for an incretin agent	Pivotal trials: substantial, established in approval
Notable warning	Glucagon activity can affect heart rate; full profile not yet labeled	Boxed warning for thyroid C-cell tumors

The mechanism difference that matters

Tirzepatide activates two receptors, GIP and GLP-1, which together curb appetite and improve insulin response. Retatrutide adds a third target, the glucagon receptor, which is thought to increase energy expenditure on top of appetite suppression. That extra lever is the reason retatrutide's Phase 2 numbers drew so much attention, but it is also why it needs careful clinical study, since glucagon activity can influence heart rate and other parameters.

Weight loss: read the numbers carefully

Retatrutide's Phase 2 results reported dose-dependent weight loss that was among the largest published for an incretin-based agent at the highest doses. Tirzepatide's weight-loss effect is well established through its pivotal trials and approval. It is tempting to line up two percentages and declare a winner, but these come from different trials, populations, and durations. There is no approved head-to-head trial, so treat any direct "X vs Y percent" claim with caution.

Side effects

Both share the GLP-1-class gastrointestinal profile: nausea, diarrhea, vomiting, and constipation, usually worst while titrating up and generally dose-related. Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors. Retatrutide's full safety profile is still being characterized in trials.

Which is "better"?

For most people the practical answer is framed by availability and supervision, not a spec sheet. Tirzepatide is an approved, prescribable medication. Retatrutide is not approved and is only appropriate in a trial or under a clinician's judgment. This page is educational and does not recommend either. A licensed provider is the right person to decide what fits your situation.

Tracking either one

If you are on a titration schedule, PepWise logs each weekly dose, handles the reconstitution and units math (see the dose converter), tracks your weight trend, and exports a provider PDF. Start free.

FAQ

What is the main difference?

Tirzepatide is a dual GIP/GLP-1 agonist and is FDA-approved. Retatrutide adds glucagon-receptor activity (triple agonist) and is investigational.

Is retatrutide better for weight loss?

Its Phase 2 numbers were among the largest reported, but it is investigational and there is no approved head-to-head trial. Cross-trial comparisons are not definitive.

Are they FDA-approved?

Tirzepatide yes (Mounjaro, Zepbound). Retatrutide no, it is still in trials.

PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Retatrutide is investigational and not FDA-approved; tirzepatide is a prescription medication. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.